You are here

Generic Version of Cipro Approved

TEL AVIV, June 10 (Reuters) - Israeli drug maker Teva Pharmaceutical Industries (NasdaqNM:TEVA - News) has received approval from the U.S. Food and Drug Administration for Ciprofloxacin Tablets in strengths of 250, 500 and 750 mg, it said on Thursday.

The tablets are the generic equivalent of Bayer's (XETRA:BAYG.DE - News) antibiotic Cipro Tablets. Annual sales of the tablets, including those of the brand product and a product sold under licensing agreement with the originator, are about $1 billion.

Teva (Tel Aviv:TEVA.TA - News), the world's biggest generic drug maker, said shipment of the product is expected to begin immediately.

Source: Teva Pharmaceuticals

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients